文献速递白血病淋巴瘤

JAK1抑制剂戈利昔替尼治疗复发/难治性大颗粒淋巴细胞白血病疗效与安全性

[Efficacy and safety of a JAK1 inhibitor for relapsed/refractory large granular lymphocytic leukemia].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2026-01-01

该研究回顾性分析16例复发/难治性LGLL患者接受戈利昔替尼单药口服治疗的资料,总体血液学缓解率87.5%,完全缓解率43.8%,中位起效时间2.9周,3级不良事件5例,短期安全性可控。

要点

  • 戈利昔替尼单药治疗复发/难治性LGLL总体血液学缓解率87.5%,完全缓解率43.8%。
  • 中位达血液学缓解时间2.9周,起效较快。
  • 药物治疗相关不良反应发生率75.0%,3级不良事件5例,短期安全性可控。

核心结论

  • 戈利昔替尼单药在复发/难治性LGLL患者中具有一定疗效,起效较快,短期安全性可控。

研究设计与样本

  • 回顾性分析2025年1月至12月中国医学科学院血液病医院16例复发/难治性LGLL患者,接受戈利昔替尼单药口服,起始剂量0.15 g每日一次。
  • 纳入T细胞LGLL 13例,自然杀伤细胞LGLL 3例。

主要发现

  • 中位随访4.0(0.8~11.1)个月,总体血液学缓解率87.5%(14/16),完全缓解率43.8%(7/16)。
  • 中位达血液学缓解时间2.9(1.4~7.6)周。
  • 药物治疗相关不良反应发生率75.0%(12/16),3级不良事件5例,包括3级粒细胞减少2例、3级血小板减少2例、3级天冬氨酸氨基转移酶升高1例,其余为1~2级。

关键数值与推荐

  • 患者总体中位年龄58(26~76)岁,基线中位HGB 58.5(43.0~101.0)g/L。
  • 基线中位中性粒细胞绝对计数1.04(0.02~4.18)×10^9/L,中位淋巴细胞绝对计数1.59(0.38~7.20)×10^9/L。
  • 基线中位大颗粒淋巴细胞计数0.60(0.06~3.63)×10^9/L,6例继发纯红细胞再生障碍。

临床怎么用

  • 戈利昔替尼单药可作为复发/难治性LGLL的一种治疗选择,需关注血液学缓解和不良反应监测。

局限性

  • 回顾性研究,样本量16例,随访时间较短。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the efficacy and safety of monotherapy with the JAK1 inhibitor golidocitinib in patients with relapsed/refractory large granular lymphocytic leukemia (LGLL) . Methods: We retrospectively analyzed 16 patients with relapsed/refractory LGLL who received oral golidocitinib monotherapy at the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences, between January and December 2025 (13 with T-LGLL and 3 with NK-LGLL). The starting dose was 0.15 g once daily, and efficacy and safety were evaluated. Results: The median age was 58 years (range, 26-76 years). At baseline, the median HGB level was 58.5 g/L (range, 43.0-101.0), the median absolute neutrophil count was 1.04×10(9)/L (range, 0.02-4.18), the median absolute lymphocyte count was 1.59×10(9)/L (range, 0.38-7.20), and the median absolute large granular lymphocyte count was 0.60×10(9)/L (range, 0.06-3.63). Six patients had secondary pure red cell aplasia. With a median follow-up of 4.0 (0.8-11.1) months, the overall hematologic response rate was 87.5% (14/16), with a median time to hematologic response of 2.9 (1.4-7.6) weeks. The complete hematologic response rate was 43.8% (7/16). The incidence of drug-associated adverse events (DAE) was 75.0% (12/16). Five patients experienced grade 3 adverse events, including grade 3 neutropenia in 2 cases, grade 3 thrombocytopenia in 2 cases, and grade 3 elevation of aspartate aminotransferase in 1 case. All remaining DAEs were grade 1-2. Conclusion: Golidocitinib monotherapy showed activity in patients with relapsed/refractory LGLL, with a rapid onset of response and a manageable short-term safety profile. 目的: 评估JAK1抑制剂戈利昔替尼治疗复发/难治性大颗粒淋巴细胞白血病(LGLL)的疗效与安全性。 方法: 回顾性分析2025年1月至12月在中国医学科学院血液病医院接受戈利昔替尼单药口服治疗的16例复发/难治性LGLL患者的临床资料(T细胞LGLL 13例,自然杀伤细胞LGLL 3例),起始剂量为0.15 g/d,评估其疗效及安全性。 结果: 患者总体中位年龄为58(26~76)岁,基线中位HGB为58.5(43.0~101.0)g/L,中位中性粒细胞绝对计数为1.04(0.02~4.18)×10(9)/L,中位淋巴细胞绝对计数为1.59(0.38~7.20)×10(9)/L,中位大颗粒淋巴细胞计数为0.60(0.06~3.63)×10(9)/L;6例继发纯红细胞再生障碍。中位随访时间为4.0(0.8~11.1)个月,总体血液学缓解率为87.5%(14/16),中位达血液学缓解时间为2.9(1.4~7.6)周,其中血液学完全缓解率为43.8%(7/16)。药物治疗相关不良反应发生率为75.0%(12/16),其中5例患者发生3级不良事件,包括3级粒细胞减少2例、3级血小板减少2例、3级天冬氨酸氨基转移酶升高1例,其余均为1~2级。 结论: 戈利昔替尼单药在复发/难治性LGLL患者中具有一定疗效,起效较快,短期安全性可控。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Tian LZ, Zhang LL, Li RN, et al. [Efficacy and safety of a JAK1 inhibitor for relapsed/refractory large granular lymphocytic leukemia]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 42706158. doi:10.3760/cma.j.cn121090-20260306-00120

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。